speedy/RINGO cell cycle regulator family member E1Genealiases: Ringo1 · SPDYB2L2 · SPDYE · WBSCR19
Q-omics provides the consensus-scored SPDYE1 profile across patient tissues and cancer cell-line models. SPDYE1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SPDYE1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, SPDYE1 RNA expression shows 20,199 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, HNSC, and KIRP as cancer lineages where SPDYE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE1 survival associations across molecular data types. SPDYE1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE1 RNA expression–survival associations across cancer types. High SPDYE1 expression shows unfavorable associations in KICH, LGG and COAD, but favorable associations in UCS, BRCA and UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SPDYE1 RNA expression.
This table summarizes SPDYE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPDYE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE1 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, CHOL, KIRC and STAD. The HNSC box plot shows higher SPDYE1 RNA expression in tumor versus normal tissue (log2 FC = +0.085, t-test p < 0.001).
This table shows molecular features associated with SPDYE1 in patient tissues and cancer cell lines. In patient samples, SPDYE1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SPDYE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
